As we observe Sarcoma Awareness Month, MIB Agents, a global leader in osteosarcoma education and collaboration, leverages OncoLens to support all aspects of their TURBO program. The OncoLens multidisciplinary cancer care platform powers patient treatment discussions, care planning, and data collection.
Atlanta, GA (Jul 19, 2022): MIB Agents has engaged OncoLens to support the organization’s Tumor Review Board for Osteosarcoma (TURBO) program. This virtual tumor board brings together a multidisciplinary team of global osteosarcoma experts to review patient cases, share experiences, and build knowledge across the sarcoma community. OncoLens’ multidisciplinary care platform captures, shares, and tracks cases immediately and over time, providing vital data to enhance care.
Osteosarcoma is an aggressive, malignant primary bone cancer. It is the most prevalent bone cancer in the United States, with between 800-1,000 new patients diagnosed each year. Osteosarcoma is also the most prevalent bone cancer impacting children and young adults.
TURBO brings together great minds in osteosarcoma research and care across geographies and institutions facilitating collaboration,” said Katie Janeway, MD, a pediatric oncologist at Dana-Farber Cancer Institute.
TURBO currently conducts six tumor boards annually, during which key opinion leaders, experts, and clinicians supporting osteosarcoma patients come together to discuss patient cases. In addition to supporting care planning, the program creates a network of expertise and insight that helps accelerate education, research focus areas, and grant opportunities. After a successful start in the US, MIB Agents will be expanding participation and increasing frequency to twelve times per year to include global osteosarcoma experts.
“For the TURBO program and global osteosarcoma community, OncoLens is helping streamline multidisciplinary clinical insights, education and access, more effectively and efficiently than ever before,” said Matteo Trucco, MD, a pediatric oncologist from Cleveland Clinic and TURBO moderator. “The collaboration that we can achieve on a global scale will help physicians from across all disciplines more efficiently review cases, share available clinical trials and promote collaboration.”
“We are proud to support the work of MIB Agents and the TURBO program,” said Anju Mathew, chief executive officer for OncoLens. “This work is another example of how a multidisciplinary cancer care platform can drive connection, collaboration, and knowledge sharing for some of the world’s most complex and difficult-to-treat cancers. We are thrilled to partner with MIB Agents and support their efforts in driving osteosarcoma research, treatment, and education.”
About MIB Agents
Founded in 2012, MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to making it better for our community of patients, caregivers, doctors, and researchers through programs, education, and research.
OncoLens is the single platform that enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure, OncoLens drives intra-enterprise, community, network, and affiliate participation in multidisciplinary care planning, tracking, and delivery. Using OncoLens, cancer providers can capture, disseminate, and track quality, best practices, and protocols. And with direct EMR and cancer registry integration, data and abstraction are automated and accelerated. The OncoLens platform allows providers to aggregate, create and track the comprehensive patient journey across the continuum. This includes maximized clinical trial participation, an extended referral stream, and the creation of a center of excellence that can be leveraged to support patient care and provider education. With OncoLens, providers can realize and expand their reputation to increase patient-driven referrals, decrease patient leakage and enhance their brand within the oncology community. More than 200 cancer centers and associations across the U.S and internationally rely on OncoLens to support their cancer programs and the care delivered.